Organon & Co. / Dermavant Sciences Ltd.

Plaque psoriasis (approved) and atopic dermatitis (sNDA filed)

10.5M US cases/yr · $3.5B US non-steroidal topical dermatology market 2024 (psoriasis + AD) · 72 VTAMA 2023 net revenue (USD MM, first full commercial year under Dermavant)

Disease Overview

Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by well-demarcated erythematous plaques with silvery scale, driven by IL-23/IL-17 axis dysregulation and keratinocyte hyperproliferation. The CDC and National Psoriasis Foundation estimate psoriasis affects approximately 7.5 million US adults, with roughly 80% presenting plaque morphology; an estimated 3 million US patients have moderate-to-severe disease eligible for systemic or biologic therapy. Atopic dermatitis (AD) is the most common inflammatory skin disease, affecting 16.5 million US adults and ~9.6 million children; it is driven by Type 2 cytokine biology (IL-4, IL-13, IL-31) layered on filaggrin-mediated barrier dysfunction. Both indications share topical corticosteroids (TCS) as cornerstone therapy despite long-standing concerns about skin atrophy, telangiectasia, tachyphylaxis, and HPA-axis suppression limiting duration and body-surface use. Non-steroidal topical options historically were limited to calcineurin inhibitors (tacrolimus, pimecrolimus) and PDE4 inhibitors (crisaborole, roflumilast foam/cream). VTAMA (tapinarof) and Zoryve (roflumilast) represent a generational shift toward steroid-free topicals that patients and dermatologists can use continuously without monitoring or tapering, particularly on sensitive sites and in pediatrics.

Competitive Landscape

The non-steroidal topical dermatology landscape is competitive and accelerating. Topical AhR agonists: VTAMA (tapinarof, Dermavant/Organon) — first-in-class, approved for plaque psoriasis (May 2022) with AD sNDA pending (PDUFA Q4 2024). Topical PDE4 inhibitors: Zoryve (roflumilast cream, Arcutis) — approved for plaque psoriasis (Jul 2022) and AD (Jul 2024), also Zoryve foam for seborrheic dermatitis; Eucrisa (crisaborole, Pfizer) — older PDE4 for AD. Topical JAK inhibitors: Opzelura (ruxolitinib, Incyte) — approved for AD and vitiligo. Topical calcineurin inhibitors: Protopic (tacrolimus, generic), Elidel (pimecrolimus, generic). Topical corticosteroids remain first-line but carry atrophy risk. In plaque psoriasis systemics, IL-23 blockade (Skyrizi/Tremfya) and IL-17 blockade (Cosentyx/Bimzelx) dominate moderate-to-severe biologics. Organon's thesis is that VTAMA's steroid-free, continuous-use positioning — particularly pending AD label expansion — differentiates against Zoryve on AhR mechanism while leveraging Organon's established women's health and dermatology primary-care field footprint.